12/3
08:44 am
nvct
Nuvectis Pharma (NASDAQ:NVCT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Nuvectis Pharma (NASDAQ:NVCT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/25
09:08 am
nvct
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC [Yahoo! Finance]
Low
Report
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC [Yahoo! Finance]
11/25
08:00 am
nvct
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
Medium
Report
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
11/8
07:05 pm
nvct
Director of Nuvectis Pharma Juan Sanchez Buys 20% More Shares [Yahoo! Finance]
Medium
Report
Director of Nuvectis Pharma Juan Sanchez Buys 20% More Shares [Yahoo! Finance]
11/4
08:15 am
nvct
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
Medium
Report
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
11/4
07:30 am
nvct
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
Medium
Report
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
10/27
08:00 am
nvct
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Low
Report
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/16
08:00 am
nvct
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Neutral
Report
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9/25
08:00 am
nvct
Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
Neutral
Report
Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors